articleThe LancetMay 11, 2017Closed access

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

THToyoaki HidaHNHiroshi NokiharaMKMasashi KondoYHYoung Hak KimKAKoichi Azuma

Aichi Cancer Center · Nagoya University · +17 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

909
total citations
FWCI
90.67
Percentile
100%
References
22
Citations per year

Authors

23

Topics & keywords

Topics
Keywords
  • Alectinib
  • Crizotinib
  • Medicine
  • Internal medicine
  • Oncology
  • Ceritinib
  • Lung cancer
  • Tolerability
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding